Wall Street analysts forecast that Affimed N.V. (NASDAQ:AFMD) will post earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Affimed N.V.’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.24). Affimed N.V. posted earnings of ($0.17) per share during the same quarter last year, which would indicate a negative year over year growth rate of 5.9%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 29th.
According to Zacks, analysts expect that Affimed N.V. will report full-year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.72). For the next year, analysts expect that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.85) to ($0.56). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Affimed N.V..
AFMD has been the subject of several research reports. ValuEngine downgraded Affimed N.V. from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Jefferies Group LLC reissued a “hold” rating and issued a $2.50 target price on shares of Affimed N.V. in a report on Thursday, July 27th.
TRADEMARK VIOLATION WARNING: “-$0.18 EPS Expected for Affimed N.V. (AFMD) This Quarter” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/11/0-18-eps-expected-for-affimed-n-v-afmd-this-quarter.html.
Shares of Affimed N.V. (NASDAQ:AFMD) traded up $0.05 during midday trading on Monday, reaching $2.00. The company’s stock had a trading volume of 355,600 shares, compared to its average volume of 278,120. The company has a quick ratio of 6.65, a current ratio of 6.43 and a debt-to-equity ratio of 0.14. Affimed N.V. has a 12 month low of $1.65 and a 12 month high of $2.95.
Hedge funds have recently modified their holdings of the stock. Creative Planning increased its position in Affimed N.V. by 7.7% in the 2nd quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the period. Virtu KCG Holdings LLC acquired a new position in Affimed N.V. in the 2nd quarter valued at about $144,000. Finally, Nationwide Fund Advisors increased its position in Affimed N.V. by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock valued at $1,038,000 after acquiring an additional 22,172 shares during the period. Hedge funds and other institutional investors own 42.34% of the company’s stock.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Get a free copy of the Zacks research report on Affimed N.V. (AFMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.